Evaxion Biotech A/S

NasdaqCM EVAX

Evaxion Biotech A/S EPS (Diluted) for the year ending December 31, 2023: USD -8.11

Evaxion Biotech A/S EPS (Diluted) is USD -8.11 for the year ending December 31, 2023, a 17.24% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Evaxion Biotech A/S EPS (Diluted) for the year ending December 31, 2022 was USD -9.80, a 22.10% change year over year.
Evaxion Biotech A/S EPS (Diluted) for the year ending December 31, 2021 was USD -12.58, a -35.71% change year over year.
Evaxion Biotech A/S EPS (Diluted) for the year ending December 31, 2020 was USD -9.27, a -34.15% change year over year.
Evaxion Biotech A/S EPS (Diluted) for the year ending December 31, 2019 was USD -6.91, a -139.93% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqCM: EVAX

Evaxion Biotech A/S

CEO	Mr. Christian Kanstrup M.Sc.
IPO Date	Feb. 5, 2021
Location	Denmark
Headquarters	Dr. Neergaards Vej
Employees	49
Sector	Healthcare
Industries Biotechnology Vaccines

Description

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Key trends

Past 5 years